Scleroderma, Systemic
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Subtype terms (2)
More specific conditions that are subtypes of Scleroderma, Systemic in the MeSH hierarchy.
- Scleroderma, Diffuse
48 drugs (25 approved, 23 experimental)
- Scleroderma, Limited
2 drugs (1 approved, 1 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (13)
Phase 3 trials (33)
- nitroglycerin
- methylprednisolone
- anifrolumab
- cannabidiol
- lymphocyte immune globulin, anti-thymocyte globulin (equine)
- rosuvastatin
- iloprost
- Filgrastim
- macitentan
- inebilizumab
- rimabotulinumtoxinB
- pirfenidone
- lidocaine
- platelets
- immune globulin (human)
- belimumab
- mycophenolate
- Anti-thymocyte Globulin (Rabbit)
- mesna
- autologous mononuclear stem cell
- autologous mesenchymal stem cells
- fludarabine
- sildenafil
- domperidone
- rituximab
- clopidogrel
- sargramostim
- sodium chloride
- relaxin
- autologous hematopoietic stem cells
- +3 more
Phase 2 trials (79)
- ringer's lactate
- riociguat
- allogeneic natural killer cells
- plerixafor
- petrolatum, white
- nerandomilast
- avenciguat
- brentuximab vedotin
- c-82
- cd3,cd19 depleted hematopoietic stem cells
- tofacitinib
- diltiazem
- valproic acid
- tacrolimus
- imatinib
- Ziritaxestat
- naltrexone
- gsk2330811
- guselkumab
- bone marrow derived mesenchymal stem cells
- aldesleukin
- albumin (Human)
- metelimumab
- hyperimmune caprine serum
- ifetroban
- itacitinib
- ixazomib
- ly3090106
- nemolizumab
- paquinimod
- +49 more
Phase 1 trials (33)
- thalidomide
- brodalumab
- buspirone
- dabigatran
- busulfan
- clobetasol
- dimethyl fumarate
- ethinyl estradiol
- nivolumab
- hyaluronidase (human recombinant)
- medi7734
- allogeneic stem cells
- semaglutide
- omeprazole
- calcipotriene
- onabotulinumtoxinA
- levonorgestrel
- cc-97540
- ct-rd06
- cd19 car-nk cells
- allorx stem cells®
- kite-363
- cd19-car-dnt cells
- ro7303509
- ctx112
- stk-009
- syncar-001
- dr-0201
- relma-cel
- mk-2225
- +3 more
Organizations
Organization Involved with Phase 4 Indications (22)
- Actelion
- United Therapeutics
- Gilead Sciences
- Eli Lilly
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Instituto Mexicano del Seguro Social
- Johns Hopkins University
- Postgraduate Institute of Medical Education and Research
- University of Groningen
- University of Michigan
- University of Rochester
- Tel Aviv University
- University of California, Los Angeles
- Government of Mexico
- A.O. Ospedale Maggiore di Lodi
- Sintesi Research Srl
- University of Sao Paulo
- Mastelli srl, via Bussana Vecchia, Sanremo, Italy
- Federal University of Sao Paulo
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (51)
- Zenyaku Kogyo Co., Ltd.
- Roche
- Allergan
- Corbus Pharmaceuticals Inc.
- Kyowa Hakko Kirin
- Shanghai Genomics, Inc.
- Boehringer Ingelheim
- MediQuest Therapeutics
- National Center for Research Resources (NCRR)
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Arizona
- University of Pittsburgh
- Alexandria University
- Boston University
- University of London
- Cornell University
- Duke University
- Georgetown University
- University of Washington
- Kanazawa University
- Medical College of Wisconsin
- Northwestern University
- Ochsner Health System
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Stanford University
- University of East Anglia
- University of Kentucky
- University of Medicine and Dentistry of New Jersey
- University of Toronto
- Wayne State University
- +21 more
Organization Involved with Phase 2 Indications (83)
- CSL Behring
- Regeneron
- Human Genome Sciences
- Kadmon
- Active Biotech AB
- Seattle Genetics
- Cambridge Antibody Technology
- Celgene
- Bristol-Myers Squibb
- Galapagos NV
- Schering-Plough
- Merck Serono
- Genentech
- Merck KGaA
- Genzyme
- Pfizer
- Sanofi
- Novartis
- Bayer
- Cumberland Pharmaceuticals
- Daval International Limited
- Digna Biotech S.L.
- Fibrocell Technologies, Inc.
- GlaxoSmithKline
- ISDIN
- Inventiva Pharma
- Iltoo Pharma
- ZonMw: The Netherlands Organisation for Health Research and Development
- Medical Research Council
- National Cancer Institute (NCI)
- +53 more
Organization Involved with Phase 1 Indications (18)
- Amgen
- MedImmune
- Biogen
- Horizon Therapeutics, LLC
- Forbius
- Baylor University
- New York Medical College
- New York University
- Pontificia Universidad Catolica de Chile
- Radboud University
- University of South Carolina
- University of Athens
- Columbia University
- City of Hope National Medical Center
- Methodist Cancer Center, Houston, Texas
- Aspreva Pharmaceuticals
- Thai Rheumatism Association
- Viela Bio
Organization Involved with Other Experimental Indications (11)